Geode Capital Management LLC Boosts Stock Holdings in Enfusion, Inc. (NYSE:ENFN)

Geode Capital Management LLC boosted its position in Enfusion, Inc. (NYSE:ENFN) by 7.3% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 1,029,366 shares of the company’s stock after purchasing an additional 70,367 shares during the period. Geode Capital Management LLC’s holdings in Enfusion were worth $9,770,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently made changes to their positions in the company. Scalar Gauge Management LLC grew its stake in shares of Enfusion by 21.8% during the 2nd quarter. Scalar Gauge Management LLC now owns 613,513 shares of the company’s stock worth $5,227,000 after acquiring an additional 110,000 shares during the period. Wellington Management Group LLP lifted its holdings in Enfusion by 6.7% during the third quarter. Wellington Management Group LLP now owns 976,296 shares of the company’s stock valued at $9,265,000 after purchasing an additional 61,032 shares during the last quarter. Renaissance Technologies LLC boosted its position in Enfusion by 167.6% during the second quarter. Renaissance Technologies LLC now owns 97,100 shares of the company’s stock worth $827,000 after purchasing an additional 60,811 shares during the period. PDT Partners LLC purchased a new position in shares of Enfusion in the third quarter worth about $867,000. Finally, Squarepoint Ops LLC bought a new stake in shares of Enfusion in the second quarter valued at approximately $683,000. 81.05% of the stock is currently owned by institutional investors.

Insider Transactions at Enfusion

In related news, CFO Bradley Herring sold 24,443 shares of the business’s stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $10.61, for a total transaction of $259,340.23. Following the completion of the transaction, the chief financial officer now directly owns 270,503 shares in the company, valued at $2,870,036.83. The trade was a 8.29 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Neal Pawar sold 21,801 shares of the company’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $10.03, for a total value of $218,664.03. Following the completion of the transaction, the chief operating officer now owns 1,143,544 shares in the company, valued at $11,469,746.32. This represents a 1.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 46,918 shares of company stock valued at $484,037. 36.44% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research firms recently weighed in on ENFN. Piper Sandler lifted their price objective on shares of Enfusion from $10.00 to $11.50 and gave the company a “neutral” rating in a research note on Monday, December 23rd. Stifel Nicolaus lifted their price target on Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a research report on Wednesday, December 18th. Three research analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $10.25.

Enfusion Price Performance

NYSE ENFN opened at $10.30 on Thursday. The company’s 50 day simple moving average is $9.95 and its two-hundred day simple moving average is $9.10. Enfusion, Inc. has a 1 year low of $7.52 and a 1 year high of $11.38. The stock has a market capitalization of $1.32 billion, a PE ratio of 257.56, a P/E/G ratio of 3.98 and a beta of 0.97.

Enfusion Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.